Stockpolly
Search
Delisting risk
DARE · NASDAQ · Biotechnology

Daré Bioscience (DARE)

Develops women's-health products spanning contraception, sexual health, menopause and vaginal health.

$0.7430
At close−0.03 (−3.53%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue12000—000100
Cost of revenue02230014201010
Gross profit1−20−300−14−20−11−10
9−15375−9242223
Research & development743533211100
333222222223
Selling & marketing000000000000
General & administrative332222222223
Other expenses0−21−300−14−20−1000
Operating income−8−5−6−7−5−5−5−4−4−1−3−3
00−12000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income001−2000000000
Income before tax−8−5−713−5−6−4−4−4−1−3−3
Net income from continuing operations−8−5−713−5−6−4−4−4−1−3−3
Net income−8−5−713−5−6−4−4−4−1−3−3
EPS, basic−$1.09−$0.69−$0.81$1.53−$0.55−$0.65−$0.50−$0.45−$0.28−$0.10−$0.21−$0.20
EPS, diluted−$1.09−$0.69−$0.81$1.52−$0.55−$0.65−$0.50−$0.45−$0.28−$0.10−$0.21−$0.20
Weighted average shares, basic8788989913141515
Weighted average shares, diluted8788989913141515
EBITDA−8−5−713−5−6−4−3−3−1−2−3
Depreciation & amortization000000000110
EBIT−8−5−713−5−6−4−4−4−1−3−3